ArticleBMC cancer2021

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.

Peng-Fei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.